Investor Overview

Company Profile
We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our collaborators – a novel product pipeline of central nervous system, or CNS, therapies to address areas of high unmet medical need, such as epilepsy, migraine, and pain.
Stock Quote
XENE (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.05 (0.99%)
Data as of April 23, 2018 2:57 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
March 28, 2018 – 8:31 a.m.
Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.
Upcoming EventsMore >>
There are currently no events scheduled.
What's New
 PDFXenon Corporate Update - Presentation
 PDF2017 10-K
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Xenon Pharmaceuticals Inc posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources